SciGro, Inc.

510 Charmany Drive

Suite 175B

Madison, WI 53562

Contact:  Kathy Muirhead

Ph: 608.824.9130

Fax: 608.824.9381



Services Provided

  • Business plan assistance
  • Scientific/technical review
  • Federal funding proposal assistance

Industry Experience

  • Healthcare/Medical services

Company Description

SciGro, a biomedical consulting firm founded by Drs. Betsy Ohlsson-Wilhelm and Kathy Muirhead in 1996, helps small businesses translate scientific discoveries and early stage technologies into successful research tools, drugs, diagnostics, and medical devices. .  Services are focused primarily on early-stage product development and include: 1) assistance with product development planning and grants-based seed funding; 2) operations management for virtual companies; and 3) scientific due diligence for investors, partners and economic development agencies.

SciGro's principals bring a strong combination of scientific expertise, academic and industry experience, and translational research skills to bear on client needs.  Together they have over 70 years of experience in managing scientific projects and product development in academia, pharmaceutical companies and start-ups.  Areas of scientific expertise include: bacteriology, biochemistry, cell & tumor biology, cellular immunotherapy; chemistry, drug & vaccine delivery, flow and image cytometry, genetics, immunology, infectious diseases, microbiology and virology.

Since its inception SciGro has provided clients with grant preparation and pre-review services that have resulted in over $20 million in feasibility/seed funding through SBIR and STTR awards from the Department of Agriculture, the Department of Defense, the National Science Foundation, and the National Institutes of Health.  SciGro is especially well positioned to help with small business grant proposals directed to the NIH because Betsy has over 20 years experience as member or chair of NIH committees reviewing BRP, P01, P41, R01, R21, R41/R42 (STTR), R43/R44 (SBIR) and S10 applications.

SciGro also assists clients with development and management of research reagent lines that leverage underutilized intellectual property, increase technology visibility and/or bring in early revenues.  For one client, a revised strategic plan incorporating stronger technical marketing support was devised and implemented, allowing them to increase revenues at an annualized rate of 30% in a relatively mature market.

Areas of Expertise

Dr. Betsy Ohlsson-Wilhelm (CEO) earned her A.B. in Biochemical Sciences and Ph.D. in Bacteriology from Harvard University and conducted post-doctoral research in biophysics (University of Chicago) and somatic cell genetics (ICR/Fox Chase Cancer Center).  During a 20-year career in academic medicine, she held senior faculty positions in microbiology, immunology, genetics and medicine (endocrinology) at the University of Rochester and the Pennsylvania State University, securing and managing multi-million dollar research grants and contracts. After joining Zynaxis, Inc., a startup developing site-selective drug and vaccine delivery systems, she rose to Sr. VP of R&D.  Her research interests include: cell-based assays and therapies; flow and image cytometry; and drug and vaccine therapies for cancer and immune, infectious or neurologic diseases. In addition to sitting on NIH review committees, Betsy acts as a reviewer for the Massachusetts Technology Transfer Council. 

Dr. Katharine Muirhead (COO) holds a B.S in Chemistry from UW-Madison, and M.S. and Ph.D. degrees in Inorganic Chemistry from the University of Illinois (Champaign-Urbana), with post-doctoral training in biochemistry (Baylor College of Medicine) and oncology (University of Rochester).  After 6 years on the Pathology faculty at the University of Rochester, she entered the pharmaceutical industry, beginning a 23 year career in discovery research, technology development and business development.  At SmithKline Beckman, she served as Sr. Investigator in Immunology and directed the Flow Cytometry Core Facility in R&D.  At Zynaxis, Inc., co-founded with colleagues from SmithKline, she rose to VP of Research and Sr. VP of New Business & Technology Development.  Her research interests include: cell tracking; cellular immunotherapy for cancer and autoimmune diseases; and methods for monitoring cell trafficking and function.  Kathy holds an adjunct faculty position at Thomas Jefferson University (Philadelphia) and serves on the Oversight Committee for the Wallace H. Coulter Foundation Translational Partnership in the UW Department of Biomedical Engineering.